ScholarWorks is upgrading a feature to improve site statistics and reporting. Users may experience interruptions in service. - July 5, 2024
ScholarWorks
Indianapolis
Communities & Collections
Browse ScholarWorks
English
Català
Čeština
Deutsch
Español
Français
Gàidhlig
Italiano
Latviešu
Magyar
Nederlands
Polski
Português
Português do Brasil
Suomi
Svenska
Türkçe
Tiếng Việt
Қазақ
বাংলা
हिंदी
Ελληνικά
Yкраї́нська
Log In
Email address
Password
Log in
or
Log in with IU Login
New user? Click here to register.
Have you forgotten your password?
Home
Statistics
Statistics for Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Loading...